New biomarkers could personalize treatment for deadly transplant complication

NCT ID NCT07305090

First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study looks for biological markers (biomarkers) in the blood or stool that can help doctors predict how severe gut graft-versus-host disease (GvHD) will become and whether a patient will respond to treatment. GvHD is a serious complication that can occur after a stem cell transplant for blood cancer, where donor immune cells attack the patient's body. The goal is to create a tool that uses these markers to personalize therapy, improving survival and quality of life for the 90 adult and pediatric participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    RECRUITING

    Bologna, Bologna, 40138, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.